CD79B and acute lymphoblastic leukemia: Moreover, an important step before clinical transition will be to preclinically test the efficacy and tolerability of PolVed in combination with standard-of-care treatments using PDX models.10,11 In this respect, the efficacy of CD79b immunotherapy could be tested in comparison or combination with small molecule inhibitors targeting the pre-BCR signaling pathway.14 Overall, gaining a better understanding of the role of the various components of the pre-BCR in leukemia development and relapse may improve diagnostic and therapeutic options in BCP-ALL.